Is it time to ban sulfonylureas?

[1] Glucose Variability and Diabetic Complications: Is It Time to Treat? [J]. DIABETES CARE, 2020, 43 (06) : 1169 - 1171

[2] Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials [J]. CLINICAL DRUG INVESTIGATION, 2019, 39 (06) : 521 - 531

[3] Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study [J]. PLOS ONE, 2019, 14 (02):

[4] A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up [J]. JOURNAL OF DIABETES RESEARCH, 2019, 2019

[5] Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2006, 22 (06) : 477 - 482

[6] Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes [J]. JAMA NETWORK OPEN, 2018, 1 (08)

[7] Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (14): : 1410 - 1418

[8] Pratipanawatr T, 2019, J DIABETES RES, V2019

[9] Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies [J]. DIABETES CARE, 2008, 31 (08) : 1672 - 1678

[10] All-cause mortality in patients on sulphonylurea monotherapy compared to metformin monotherapy in a nation-wide cohort [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 147 : 62 - 66

[1] Glucose Variability and Diabetic Complications: Is It Time to Treat? [J]. DIABETES CARE, 2020, 43 (06) : 1169 - 1171

[2] Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials [J]. CLINICAL DRUG INVESTIGATION, 2019, 39 (06) : 521 - 531

[3] Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study [J]. PLOS ONE, 2019, 14 (02):

[4] A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up [J]. JOURNAL OF DIABETES RESEARCH, 2019, 2019

[5] Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2006, 22 (06) : 477 - 482

[6] Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes [J]. JAMA NETWORK OPEN, 2018, 1 (08)

[7] Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (14): : 1410 - 1418

[8] Pratipanawatr T, 2019, J DIABETES RES, V2019

[9] Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies [J]. DIABETES CARE, 2008, 31 (08) : 1672 - 1678

[10] All-cause mortality in patients on sulphonylurea monotherapy compared to metformin monotherapy in a nation-wide cohort [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 147 : 62 - 66